How to Conduct a Systematic Literature Review on Cognitive and Sleep Peptides

Most researchers assume that a systematic literature review begins in the search box of a database. In reality, entering search terms before establishing rigorous boundaries almost guarantees an unreliable synthesis. This is especially true for brain-active peptides, where commercial vernacular frequently blurs into scientific literature.

The category of cognitive and sleep peptides does not represent a single, chemically uniform class of substances. Instead, it spans endogenous neuropeptides, synthetic peptide fragments, neuroendocrine hormones, and non-peptide receptor agonists. Investigating these molecules requires parsing distinct layers of evidence ranging from cell-free binding assays to double-blind clinical trials. Without a systematic protocol established beforehand, researchers risk combining disparate experimental models into misleading conclusions.

A systematic literature review is not a narrative summary with an expanded reference list. It is an explicit, reproducible investigation that treats published and unpublished studies as empirical data. Conducting such a review requires prespecified eligibility criteria, systematic bibliographic searching, transparent screening, structured risk of bias appraisal, and disciplined synthesis. This guide details every stage of conducting a systematic review on peptide interventions that influence cognitive outcomes and sleep architecture.

Define the Scope Before Querying the Literature

Setting the scope requires establishing strict chemical and biological criteria for what qualifies as an intervention. In peptide research, the boundary between an endogenous signaling molecule and a synthetic pharmaceutical is often fluid. The research team must resolve whether the review includes only endogenous neuropeptides, synthetic analogs, bioactive fragments, or any ligand acting on a neuropeptide receptor. According to the National Library of Medicine Medical Subject Headings (MeSH) definition, neuropeptides are peptides released by neurons as intercellular messengers. The same definition notes that many of these molecules also function as hormones released by non-neuronal tissues.

Failing to define these boundaries causes profound classification errors during screening. For instance, a review focused on neuropeptide signaling might include small-molecule antagonists that target orexin or vasopressin receptors. Conversely, a review focused strictly on peptide therapeutics must exclude non-peptide molecules, even if they modulate the exact same pathway. Researchers should classify candidate interventions into distinct chemical tiers before running searches:

Endogenous neuropeptides and whole peptide hormones.
Synthetic analogs modified for enzymatic stability or cross-membrane transport.
Peptide fragments or truncated sequences maintaining receptor affinity.
Non-peptide small molecules that act as agonists or antagonists at peptide receptors.

Each tier represents fundamentally distinct pharmacological behavior. Peptide fragments often possess altered pharmacokinetic profiles compared to their parent sequences. Synthetic modifications such as D-amino acid substitutions or cyclization change bioavailability across the blood-brain barrier. When designing a protocol within cognitive and sleep peptide research, investigators must explicitly state which tiers are eligible for inclusion.

Outcome parameters require equally rigorous definition. Generic concepts such as cognitive performance or sleep quality cannot serve as operable inclusion criteria. Cognition encompasses executive function, spatial memory, working memory, processing speed, and sustained attention. Sleep outcomes encompass polysomnographic sleep architecture, sleep onset latency, total sleep time, slow-wave sleep duration, and subjective sleepiness indices. The protocol should catalog eligible endpoints and determine whether molecular biomarkers, such as receptor expression levels, qualify as primary outcomes or remain exploratory.

Separate Evidence Strata to Prevent False Translation

Systematic reviews in pharmacology frequently fail because they pool preclinical discoveries with human trial results. Rodent behavioral assays cannot simply be treated as proxies for human cognitive testing. For example, a peptide that reduces latency in a Morris water maze does not automatically improve memory in healthy human adults. Systematic reviewers must construct an evidence map that separates laboratory models from clinical outcomes.

In vitro studies provide mechanistic data regarding receptor binding kinetics, secondary messenger signaling, and metabolic degradation. However, these models cannot evaluate blood-brain barrier penetration, clearance dynamics, or complex network physiology. When reviewing cellular data, researchers must evaluate separating receptor binding from biological effect to avoid overestimating therapeutic potential. In vitro findings should occupy a distinct stratum within the review protocol.

Animal intervention experiments provide critical systemic context regarding bioavailability and behavioral changes. Unfortunately, methodological quality and reporting transparency in animal literature remain substantial challenges across biomedical research. Preclinical systematic review guidance from Cochrane highlights widespread failures in animal studies to report fundamental safeguards. These unreported practices include sequence randomization, allocation concealment, blinded drug administration, and blinded outcome assessment. Combining unblinded animal data with blinded clinical trials inevitably distorts the true certainty of an effect.

Human clinical trials occupy the highest stratum in the translational hierarchy, yet they introduce their own complexities. Clinical studies may enroll healthy volunteers, shift workers, or populations diagnosed with neurodegenerative disorders or chronic insomnia. A peptide altering sleep architecture in severe sleep apnea may exert entirely different effects in individuals without baseline impairment. The review protocol must establish separate evidence tables for each model type. Treating animal, mechanistic, and human data as discrete tiers ensures that biological plausibility is never confused with clinical proof.

Formulate Targeted Questions Using Structured Frameworks

A systematic review requires a sharply focused research question. Vague queries, such as asking whether peptides improve sleep, leave critical screening variables undefined. Frameworks like PICO provide necessary discipline:

Population: Define the species, age range, sex, baseline health status, or disease model.
Intervention: Specify the precise peptide identity, sequence, chemical modifications, vehicle, route of administration, and treatment duration.
Comparator: Identify acceptable control conditions, such as vehicle injections, sham procedures, active reference drugs, or untreated controls.
Outcomes: Prespecify validated cognitive tests, objective polysomnographic recordings, subjective questionnaires, or mechanistic markers.

The framework must be adjusted when evaluating diverse experimental literature. A human intervention question might ask: In adult humans with primary insomnia, does intranasal administration of a specified peptide, compared with vehicle placebo, improve polysomnographically measured sleep efficiency? This question establishes unambiguous boundaries for screening abstracts.

Preclinical questions demand equal specificity regarding biological systems. A preclinical question might ask: In adult male rodent models of acute sleep deprivation, does systemic administration of a specified peptide analog, compared with saline vehicle, alter novel object recognition test performance? By specifying the model, the exact behavioral paradigm, and the comparator, reviewers prevent ambiguous screening decisions.

Reviewers should consider establishing independent PICO frameworks for human efficacy and animal mechanistic studies. Attempting to force both domains into a single matrix frequently causes confusion during data extraction. Documenting separate eligibility profiles clarifies the review architecture. Detailed guidance on structuring compound evidence profiles helps investigators maintain consistent operational definitions across study designs.

A comprehensive protocol must be drafted and archived before searches are conducted. Prospective registration creates an immutable public record of the study design. The International Prospective Register of Systematic Reviews (PROSPERO) provides open registration for health-related reviews. PROSPERO requires prospective submission of review questions, eligibility parameters, search strategies, and planned synthesis methods. When conducting animal-only systematic reviews, platforms like CAMARADES or the Open Science Framework provide suitable alternatives for protocol registration.

Select Databases and Supplementary Trial Registries

A rigorous search for cognitive and sleep peptides must look across multiple disciplines. Neuroscience, biochemistry, sleep medicine, and clinical pharmacology are distributed across several index platforms. Relying exclusively on a single platform guarantees substantial omissions. Cochrane searching guidance emphasizes consulting multiple bibliographic databases, regional databases, specialized registers, and grey literature sources.

PubMed remains an indispensable foundation for biomedical investigations. The PubMed platform indexes over 40 million citations across life sciences literature. Its core database, MEDLINE, includes more than 31 million curated references characterized by MeSH indexing. MeSH provides controlled vocabulary tags that group variant terminologies under uniform subject headings. However, PubMed does not cover every specialized pharmacology or psychological record.

Comprehensive reviews must incorporate Embase alongside PubMed. Embase features extensive European pharmacology coverage and utilizes the Emtree controlled vocabulary system. Emtree often indexes drug compounds, chemical analogs, and experimental formulations with greater granularity than MEDLINE. Additionally, APA PsycINFO is essential for locating cognitive testing paradigms, behavioral tasks, and psychometric assessments that life science databases may index inadequately. The Cochrane Central Register of Controlled Trials (CENTRAL) should always be searched to capture controlled intervention studies.

Trial registries serve as an essential defense against publication bias. Negative or inconclusive trials on experimental peptides are frequently left unpublished in academic journals. ClinicalTrials.gov hosts records for hundreds of thousands of registered studies globally. The World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) aggregates registry data from multiple international repositories. Registry entries provide prospective trial details, protocol endpoints, and occasionally tabular results that never appear in peer-reviewed journals.

Supplementary search methods must accompany database queries. Hand-searching the reference lists of eligible studies and pertinent review articles identifies older or idiosyncratically indexed literature. Forward citation tracking through platforms like Web of Science or Scopus reveals recent experiments that cited landmark peptide studies. Any supplementary sources utilized must be systematically documented alongside formal database searches.

Construct Sensitive and Reproducible Search Strategies

Designing a search strategy requires balancing sensitivity and precision. Sensitivity represents the ability to capture all truly relevant studies. Precision represents the proportion of retrieved records that actually meet the inclusion criteria. Cochrane search standards explicitly advise reviewers to maximize sensitivity, even if it requires screening a larger volume of irrelevant titles. Prematurely restricting search parameters risks omitting crucial evidence.

Search syntax should be constructed by combining major conceptual blocks using Boolean logic. A typical review strategy joins the intervention concept with the outcome concept using the AND operator. Within the intervention concept, every known name, synonym, fragment identifier, and laboratory code must be joined using the OR operator. The outcome concept must similarly assemble all synonyms for cognition, memory, sleep architecture, and electroencephalographic measures using the OR operator.

Controlled vocabulary terms must always be coupled with free-text terms. Controlled vocabularies like MeSH ensure standard indexing, but recently published literature often appears as unindexed pre-medline citations. Text words searched within titles and abstracts capture the newest publications before indexing occurs. For example, when searching for neuropeptides, an effective MEDLINE strategy pairs the MeSH descriptor "Neuropeptides" with free-text phrases across titles and abstracts. Truncation symbols and wildcards must be adapted carefully according to each database's specific search syntax.

Chemical terminology for peptides presents distinct indexing challenges. Synthetic peptides often appear under varying names across literature:

Systematic chemical nomenclature (IUPAC designations).
Standard amino acid sequences written in one-letter or three-letter codes.
Laboratory experimental identifiers containing letters, hyphens, and numbers.
International Nonproprietary Names (INN) assigned by regulatory authorities.
Proprietary research codes or regional commercial designations.

Reviewers should avoid applying overly restrictive study-design filters during the search phase. While validated methodological search filters exist for human randomized controlled trials, applying them to preclinical literature is problematic. Preclinical study-design filters frequently introduce high rates of false-negative exclusions. Furthermore, researchers must preserve the exact line-by-line strategy, date of execution, platform interface, and limits applied for every database. Adhering to the PRISMA-S checklist ensures that every search string remains fully reproducible for external peer reviewers.

Screen Literature and Document Exclusions Transparently

Once database searches conclude, all identified citations must be gathered and deduplicated. Specialized systematic review software streamlines reference management and prevents accidental exclusions. Duplicate records resulting from multi-database overlaps must be identified and removed systematically. Reviewers must document the starting count of identified records alongside the exact number of duplicates removed.

Screening proceeds across two distinct, consecutive tiers. The first tier involves screening titles and abstracts against prespecified inclusion and exclusion criteria. Records that clearly fail eligibility criteria are eliminated immediately. When title and abstract text provide insufficient clarity, the record must be retained for full-text inspection. The second tier involves retrieving the complete full-text articles for all remaining candidates.

To minimize selection bias, two independent reviewers should screen titles, abstracts, and full texts. Discrepancies between screeners must be resolved through discussion or consultation with a third adjudicator. If a solo reviewer must perform screening due to resource limits, that constraint must be stated openly in the final report. Under no circumstances should an individual screening effort be described as an independent dual-review process.

During the full-text assessment, investigators must document the primary reason for every exclusion. Generalized reasons like "not relevant" are unacceptable in systematic reviews. Exclusions must be categorized using standardized labels:

Ineligible intervention (unrelated compound, non-peptide molecule, or ambiguous sequence).
Ineligible population (non-target species, wrong clinical diagnosis, or in vitro model).
Ineligible comparator (lacks appropriate vehicle control or baseline comparison).
Ineligible outcome (no valid cognitive or sleep measures reported).
Ineligible publication type (conference abstract without usable data, commentary, or narrative review).
Duplicate data report (redundant publication of an identical patient or animal cohort).

The entire selection process must be mapped within a PRISMA flow diagram. The PRISMA 2020 statement details flow diagram architectures for original reviews and updated reviews. The diagram maps the precise flow of evidence from initial identification through final inclusion. Readers must be able to verify exactly how thousands of database records were winnowed down to the final included studies.

Handling intervention ambiguity requires strict protocol procedures. If a published paper uses an ambiguous acronym that could designate multiple unrelated compounds, reviewers must not make assumptions. Authors should be contacted directly to request clarifying chemical documentation. If the peptide sequence cannot be verified, the paper must be excluded with a documented notation of chemical ambiguity.

Extract Variables and Assess Methodological Risk of Bias

Data extraction translates qualitative text and numerical study results into structured, standardized tables. Extraction should be performed using piloted extraction forms to maintain consistency across the team. Extracted variables must capture experimental parameters alongside outcome values:

Study Identifiers: Primary author, publication year, country, funding source, and declared conflicts of interest.
Model Characteristics: Organism, species, strain, sex, age, baseline cognitive or sleep status, and housing conditions.
Intervention Specifics: Exact peptide sequence, chemical salt, purity verification, formulation, vehicle, route of delivery, dose, frequency, and total duration.
Methodological Details: Allocation method, blinding protocols, comparator details, sample sizes per arm, and attrition rates.
Outcome Data: Primary and secondary endpoints, measurement time points, objective testing instruments, raw mean values, standard deviations, and statistical effect sizes.

Extracting laboratory details is crucial when interpreting preclinical peptide literature. Preclinical peptide experiments often omit critical parameters like delivery vehicle composition or injection timing. Without these parameters, biological responses cannot be properly compared.

Risk of bias assessment differs fundamentally from reporting quality or biological plausibility. A study may present fascinating mechanistic discoveries while possessing a high risk of methodological bias. Reviewers must select an assessment tool that matches the specific study design of the included records. Indiscriminately applying a clinical assessment tool to laboratory animal experiments invalidates the methodological appraisal.

For animal intervention studies, the SYRCLE Risk of Bias tool is the gold standard. Developed by the SYRCLE network based on the Cochrane Risk of Bias tool, it addresses ten specific methodological domains:

Sequence generation (selection bias).
Baseline characteristics similarity across groups (selection bias).
Allocation concealment (selection bias).
Random housing of experimental animals (performance bias).
Caregiver and investigator blinding (performance bias).
Randomized outcome assessment (detection bias).
Blinded outcome assessment (detection bias).
Incomplete outcome data handling (attrition bias).
Selective outcome reporting (reporting bias).
Other sources of bias, such as contamination or funding conflicts.

For human randomized controlled trials, the revised Cochrane Risk of Bias tool (RoB 2) provides the standard evaluation framework. Observational human studies require tools such as ROBINS-I. Each domain should be evaluated with transparent supporting text rather than simple checkmarks. High-risk studies should not be silently removed. Instead, they must be retained in the synthesis to show how bias influences effect sizes across the literature.

Synthesize Findings Without Flattening Biological Reality

Synthesizing peptide literature requires deciding whether mathematical meta-analysis is methodologically defensible. A meta-analysis should never be conducted simply because multiple studies present numerical values. If studies feature extensive heterogeneity in peptide structures, administration routes, animal models, or cognitive tests, calculating a pooled effect estimate produces meaningless numbers.

When heterogeneity is high, a structured narrative synthesis represents the most rigorous approach. A narrative synthesis organizes findings logically across defined conceptual categories. Reviewers should group outcomes by peptide classification, target receptor, delivery route, and physiological model. Evidence tables must present findings clearly without conflating divergent endpoints:

Human double-blind trials measuring objective polysomnography.
Human trials assessing subjective sleep ratings or psychometric scales.
In vivo animal experiments evaluating spatial or executive behavioral performance.
Ex vivo and in vitro experiments demonstrating cellular signaling pathways.

When studies are sufficiently homogeneous to warrant quantitative pooling, random-effects meta-analytic models are generally preferred. Fixed-effect models assume that all studies share an identical true effect size. That assumption rarely holds true in peptide literature, where experimental conditions differ across laboratories. Reviewers must calculate standardized mean differences for continuous cognitive scores and assess statistical heterogeneity using the I-squared statistic. Subgroup analyses should be prespecified in the protocol to investigate whether administration route or dosage alters outcomes.

Finally, reviewers should evaluate the overall certainty of evidence using the GRADE framework. GRADE categorizes evidence certainty into four discrete levels: high, moderate, low, and very low. Randomized human trials begin at high certainty, while observational studies begin at low certainty. The body of evidence can be downgraded based on five established domains:

Risk of bias across included studies.
Inconsistency of findings across laboratories.
Indirectness of the study populations, interventions, or outcome measures.
Imprecision resulting from small sample sizes or wide confidence intervals.
Publication bias detected through funnel plots or registry analyses.

Preclinical evidence generally rates as low or very low certainty regarding clinical translation. Transparently assigning these certainty ratings prevents reviewers from overstating laboratory discoveries.

Account for Peptide Identity and Laboratory Ambiguities

A hidden pitfall in peptide literature reviews is assuming that a published compound name guarantees its chemical identity. Academic publications frequently purchase peptide materials from third-party manufacturers without performing independent chemical verification. In some cases, published studies report biological findings using materials that were improperly characterized, degraded, or contaminated with synthesis byproducts. Reviewers must account for chemical characterization when extracting study data.

Peptide synthesis is complex, and standard purity reporting can be misleading. High-performance liquid chromatography (HPLC) provides data regarding chromatographic purity by measuring relative peak area. However, HPLC purity alone does not verify the structural identity of the peptide. Mass spectrometry (MS) is necessary to confirm molecular weight and sequence integrity. A study reporting 98 percent HPLC purity might still utilize a peptide containing truncated sequences or counterion salts if mass spectrometry was omitted.

Reviewers should note whether published studies document complete analytical testing. An analytical Certificate of Analysis (COA) confirms only what was measured in a specific test sample. A COA for a single research batch cannot prove the chemical composition of different lots used across multiple experiments. Reviewers should record whether authors validated peptide identity, counterion content, and net peptide content internally:

Gross peptide weight includes the peptide molecule, counterion salts, and residual water.
Net peptide content reflects the actual percentage of peptide mass within the lyophilized powder.
Trifluoroacetic acid (TFA) counterions from solid-phase peptide synthesis can exert independent neurobiological effects in experimental models.
Peptide oxidation, particularly at methionine or cysteine residues, can alter receptor binding and biological activity.

Detailed parameters on verifying peptide identity and purity standards should inform data extraction protocols. When an experimental study fails to document analytical verification or solvent composition, reviewers must record that reporting omission.

Chemical ambiguity directly affects how risk of bias is evaluated. If an experiment uses unverified peptide material, observed cognitive or sleep responses cannot be linked to the molecule with confidence. Reviewers should highlight chemical reporting omissions alongside methodological risks of bias. Documenting laboratory reporting limitations ensures that systematic reviews remain scientifically rigorous.

Key Takeaways

Define chemical and biological boundaries beforehand, separating endogenous neuropeptides, synthetic analogs, fragments, and non-peptide receptor ligands.
Maintain separate evidence tables for in vitro, animal behavioral, and human clinical studies to prevent inappropriate translational claims.
Formulate precise, structured research questions using PICO frameworks and register the complete review protocol prospectively on platforms like PROSPERO.
Search across multiple databases, including PubMed, Embase, and PsycINFO, while searching trial registries to identify unpublished or ongoing studies.
Construct sensitive search strategies that balance controlled vocabularies like MeSH with extensive free-text synonyms, sequence codes, and laboratory acronyms.
Execute screening in two independent tiers using standardized exclusion reasons, and map all record selections within a transparent PRISMA flow diagram.
Evaluate methodological quality using design-appropriate tools, such as the SYRCLE Risk of Bias tool for animal experiments and RoB 2 for clinical trials.
Avoid pooling heterogeneous studies into premature meta-analyses, opting instead for structured narrative syntheses evaluated under the GRADE framework.
Extract chemical characterization details, accounting for whether studies confirmed peptide identity, net peptide content, and counterion presence.

Rigorous literature reviews depend on explicit protocols, exhaustive searches, transparent exclusions, and restrained synthesis that respects the boundaries of experimental evidence.

Sources

Introducing / CaliLean Field Notes

A little more
perspective.

An editorial letter for curious minds. Thoughtful reading, questions worth keeping and the sources behind them.

Explore Field Notes Join the list for the first edition

Back to all resources Back to top